Investigation of OFA-iLRP targeted cancer immunother apy against lung cancer
Project/Area Number |
20790136
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Medical pharmacy
|
Research Institution | The University of Tokushima |
Principal Investigator |
ABE Shinji The University of Tokushima, 医学部・歯学部附属病院, 助教 (00403717)
|
Project Period (FY) |
2008 – 2009
|
Project Status |
Completed (Fiscal Year 2009)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2008: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | トランスレーショナルリサーチ / 癌 / 免疫療法 / 癌抗原 |
Research Abstract |
In this study, I have investigated whether OFA-iLRP is expressed on human lung cancer tissues and whether OFA-iLRP peptides treated dendritic cells induce OFA-iLRP specific CTLs. Our results show that most human lung cancer tissues express OFA-iLRP and dendritic cells treated by OFA-iLRP peptides induce CTLs. Considering these results, OFA-iLRP may represent a suitable target against advanced lung cancer.
|
Report
(3 results)
Research Products
(2 results)